BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,138 filers reported holding BAXTER INTL INC in Q4 2019. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $252,127,335 | -13.8% | 4,946,583 | -8.9% | 5.28% | -18.9% |
Q3 2022 | $292,444,000 | -20.9% | 5,429,702 | -5.7% | 6.51% | -11.4% |
Q2 2022 | $369,852,000 | -2.2% | 5,758,247 | +18.1% | 7.34% | +8.5% |
Q1 2022 | $378,153,000 | +7.9% | 4,876,877 | +19.4% | 6.77% | +9.7% |
Q4 2021 | $350,589,000 | -1.2% | 4,084,218 | -7.5% | 6.17% | -5.1% |
Q3 2021 | $354,953,000 | +24.5% | 4,413,191 | +24.6% | 6.50% | +27.9% |
Q2 2021 | $285,125,000 | +29.4% | 3,541,919 | +35.6% | 5.08% | +23.5% |
Q1 2021 | $220,369,000 | +226.6% | 2,612,868 | +210.7% | 4.12% | +216.4% |
Q4 2020 | $67,468,000 | +508.5% | 840,832 | +509.9% | 1.30% | +400.4% |
Q3 2020 | $11,087,000 | +3269.9% | 137,865 | +3510.9% | 0.26% | +2788.9% |
Q2 2020 | $329,000 | +12.7% | 3,818 | +6.3% | 0.01% | -10.0% |
Q1 2020 | $292,000 | -68.4% | 3,593 | -67.5% | 0.01% | -66.7% |
Q4 2019 | $925,000 | -84.8% | 11,060 | -84.1% | 0.03% | -86.9% |
Q3 2019 | $6,075,000 | -39.9% | 69,455 | -43.7% | 0.23% | -46.5% |
Q2 2019 | $10,104,000 | -58.8% | 123,365 | -59.1% | 0.43% | -66.4% |
Q1 2019 | $24,543,000 | -10.3% | 301,847 | -27.4% | 1.27% | -30.9% |
Q4 2018 | $27,356,000 | – | 415,619 | – | 1.84% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |